The approval of sintilimab for classical hodgkin's lymphoma: Views and perspectives of anti-pd-1/pd-l1 antibodies in china

Mi Deng

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)54-55
Number of pages2
JournalAntibody Therapeutics
Issue number2
StatePublished - 2019


  • Checkpoint inhibitor
  • Checkpoint inhibitor
  • Classic Hodgkin's lymphoma
  • PD-1 antibody
  • Sintilimab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this